mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report
Patricia Ibeas, Blanca Cantos, Mariano ProvencioClinical Oncology Department, Hospital Puerta de Hierro Majadahonda, Madrid, SpainAbstract: Hodgkin’s disease is curable in 90% of the cases diagnosed in early stages (I and II) and in 70% of all patients who suffer from the disease. Refr...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2011
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e113c6da2f18452db564f0ea77074c2e |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e113c6da2f18452db564f0ea77074c2e |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e113c6da2f18452db564f0ea77074c2e2021-12-02T04:55:57ZmTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report1179-9889https://doaj.org/article/e113c6da2f18452db564f0ea77074c2e2011-11-01T00:00:00Zhttp://www.dovepress.com/mtor-inhibitor-in-the-treatment-of-hodgkinrsquos-lymphoma-a-case-repor-a8613https://doaj.org/toc/1179-9889Patricia Ibeas, Blanca Cantos, Mariano ProvencioClinical Oncology Department, Hospital Puerta de Hierro Majadahonda, Madrid, SpainAbstract: Hodgkin’s disease is curable in 90% of the cases diagnosed in early stages (I and II) and in 70% of all patients who suffer from the disease. Refractory disease occurs in 10%–15% of cases and is still a clinical challenge. Its treatment is based on intensive chemotherapy regimens with transplantation, but there are patients who relapse after transplantation who have a poor prognosis. At this point in time, there is a lack of effective treatment options with proven efficacy and there is a real need to investigate new treatment drugs with different mechanisms of action. A persistent activation of mTOR signaling has been identified in leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple myeloma. Everolimus, an mTOR kinase inhibitor, is being used as an option in these cases with encouraging results. Here, the authors report their experience with a patient treated with everolimus.Keywords: everolimus, positron emission tomography, chemotherapyProvencio M.Cantos BIbeas PDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2011, Iss default, Pp 19-22 (2011) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Diseases of the blood and blood-forming organs RC633-647.5 |
| spellingShingle |
Diseases of the blood and blood-forming organs RC633-647.5 Provencio M. Cantos B Ibeas P mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report |
| description |
Patricia Ibeas, Blanca Cantos, Mariano ProvencioClinical Oncology Department, Hospital Puerta de Hierro Majadahonda, Madrid, SpainAbstract: Hodgkin’s disease is curable in 90% of the cases diagnosed in early stages (I and II) and in 70% of all patients who suffer from the disease. Refractory disease occurs in 10%–15% of cases and is still a clinical challenge. Its treatment is based on intensive chemotherapy regimens with transplantation, but there are patients who relapse after transplantation who have a poor prognosis. At this point in time, there is a lack of effective treatment options with proven efficacy and there is a real need to investigate new treatment drugs with different mechanisms of action. A persistent activation of mTOR signaling has been identified in leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple myeloma. Everolimus, an mTOR kinase inhibitor, is being used as an option in these cases with encouraging results. Here, the authors report their experience with a patient treated with everolimus.Keywords: everolimus, positron emission tomography, chemotherapy |
| format |
article |
| author |
Provencio M. Cantos B Ibeas P |
| author_facet |
Provencio M. Cantos B Ibeas P |
| author_sort |
Provencio M. |
| title |
mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report |
| title_short |
mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report |
| title_full |
mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report |
| title_fullStr |
mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report |
| title_full_unstemmed |
mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report |
| title_sort |
mtor inhibitor in the treatment of hodgkin’s lymphoma: a case report |
| publisher |
Dove Medical Press |
| publishDate |
2011 |
| url |
https://doaj.org/article/e113c6da2f18452db564f0ea77074c2e |
| work_keys_str_mv |
AT provenciom mtorinhibitorinthetreatmentofhodgkinamprsquoslymphomaacasereport AT cantosb mtorinhibitorinthetreatmentofhodgkinamprsquoslymphomaacasereport AT ibeasp mtorinhibitorinthetreatmentofhodgkinamprsquoslymphomaacasereport |
| _version_ |
1718400983222976512 |